Condition
Refractory or Relapsed Multiple Myeloma
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (3)
P 3 (1)
Trial Status
Unknown4
Recruiting1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06952478Phase 3RecruitingPrimary
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
NCT03090659Phase 1UnknownPrimary
LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
NCT03380039Not ApplicableUnknownPrimary
Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma
NCT03716856Phase 1UnknownPrimary
Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
NCT03674463Phase 1UnknownPrimary
LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
Showing all 5 trials